Literature DB >> 29519954

Fibroblast Growth Factor 23 Associates with Death in Critically Ill Patients.

David E Leaf1, Edward D Siew2, Michele F Eisenga2, Karandeep Singh2, Finnian R Mc Causland2, Anand Srivastava2, T Alp Ikizler2, Lorraine B Ware2, Adit A Ginde2, John A Kellum2, Paul M Palevsky2, Myles Wolf2, Sushrut S Waikar2.   

Abstract

BACKGROUND AND OBJECTIVES: Dysregulated mineral metabolism is a common and potentially maladaptive feature of critical illness, especially in patients with AKI, but its association with death has not been comprehensively investigated. We sought to determine whether elevated plasma levels of the osteocyte-derived, vitamin D-regulating hormone, fibroblast growth factor 23 (FGF23), are prospectively associated with death in critically ill patients with AKI requiring RRT, and in a general cohort of critically ill patients with and without AKI. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We measured plasma FGF23 and other mineral metabolite levels in two cohorts of critically ill patients (n=1527). We included 817 patients with AKI requiring RRT who enrolled in the ARF Trial Network (ATN) study, and 710 patients with and without AKI who enrolled in the Validating Acute Lung Injury biomarkers for Diagnosis (VALID) study. We hypothesized that higher FGF23 levels at enrollment are independently associated with higher 60-day mortality.
RESULTS: In the ATN study, patients in the highest compared with lowest quartiles of C-terminal (cFGF23) and intact FGF23 (iFGF23) had 3.84 (95% confidence interval, 2.31 to 6.41) and 2.08 (95% confidence interval, 1.03 to 4.21) fold higher odds of death, respectively, after adjustment for demographics, comorbidities, and severity of illness. In contrast, plasma/serum levels of parathyroid hormone, vitamin D metabolites, calcium, and phosphate were not associated with 60-day mortality. In the VALID study, patients in the highest compared with lowest quartiles of cFGF23 and iFGF23 had 3.52 (95% confidence interval, 1.96 to 6.33) and 1.93 (95% confidence interval, 1.12 to 3.33) fold higher adjusted odds of death.
CONCLUSIONS: Higher FGF23 levels are independently associated with greater mortality in critically ill patients.
Copyright © 2018 by the American Society of Nephrology.

Entities:  

Keywords:  Acute Kidney Injury; Acute Lung Injury; Biomarkers; Calcium, Dietary; Cohort Studies; Comorbidity; Confidence Intervals; Critical Illness; Demography; Fibroblast Growth Factors; Humans; Minerals; Osteocytes; Phosphates; Renal Replacement Therapy; Vitamin D; acute renal failure; fibroblast growth factor 23; parathyroid hormone; renal dialysis

Mesh:

Substances:

Year:  2018        PMID: 29519954      PMCID: PMC5969465          DOI: 10.2215/CJN.10810917

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  42 in total

1.  FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality.

Authors:  Victoria Shalhoub; Edward M Shatzen; Sabrina C Ward; James Davis; Jennitte Stevens; Vivian Bi; Lisa Renshaw; Nessa Hawkins; Wei Wang; Ching Chen; Mei-Mei Tsai; Russell C Cattley; Thomas J Wronski; Xuechen Xia; Xiaodong Li; Charles Henley; Michael Eschenberg; William G Richards
Journal:  J Clin Invest       Date:  2012-06-25       Impact factor: 14.808

2.  Vitamin D deficiency in critically ill patients.

Authors:  Paul Lee; John A Eisman; Jacqueline R Center
Journal:  N Engl J Med       Date:  2009-04-30       Impact factor: 91.245

3.  Plasma inflammatory and apoptosis markers are associated with dialysis dependence and death among critically ill patients receiving renal replacement therapy.

Authors:  Raghavan Murugan; Xiaoyan Wen; Nilesh Shah; Minjae Lee; Lan Kong; Francis Pike; Christopher Keener; Mark Unruh; Kevin Finkel; Anitha Vijayan; Paul M Palevsky; Emil Paganini; Melinda Carter; Michele Elder; John A Kellum
Journal:  Nephrol Dial Transplant       Date:  2014-03-11       Impact factor: 5.992

4.  FGF-23 levels in patients with AKI and risk of adverse outcomes.

Authors:  David E Leaf; Myles Wolf; Sushrut S Waikar; Herbert Chase; Marta Christov; Serge Cremers; Leonard Stern
Journal:  Clin J Am Soc Nephrol       Date:  2012-06-14       Impact factor: 8.237

5.  Robust variance estimation for the case-cohort design.

Authors:  W E Barlow
Journal:  Biometrics       Date:  1994-12       Impact factor: 2.571

Review 6.  Antibacterial effects of vitamin D.

Authors:  Martin Hewison
Journal:  Nat Rev Endocrinol       Date:  2011-01-25       Impact factor: 43.330

7.  Therapeutic Effects of FGF23 c-tail Fc in a Murine Preclinical Model of X-Linked Hypophosphatemia Via the Selective Modulation of Phosphate Reabsorption.

Authors:  Kristen Johnson; Kymberly Levine; Joseph Sergi; Jean Chamoun; Rachel Roach; Jacqueline Vekich; Mike Favis; Mark Horn; Xianjun Cao; Brian Miller; William Snyder; Dikran Aivazian; William Reagan; Edwin Berryman; Jennifer Colangelo; Victoria Markiewicz; Cedo M Bagi; Thomas P Brown; Anthony Coyle; Moosa Mohammadi; Jeanne Magram
Journal:  J Bone Miner Res       Date:  2017-08-25       Impact factor: 6.741

8.  Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23.

Authors: 
Journal:  Nat Genet       Date:  2000-11       Impact factor: 38.330

9.  Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes.

Authors:  Justine Bacchetta; Jessica L Sea; Rene F Chun; Thomas S Lisse; Katherine Wesseling-Perry; Barbara Gales; John S Adams; Isidro B Salusky; Martin Hewison
Journal:  J Bone Miner Res       Date:  2013-01       Impact factor: 6.741

10.  FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability.

Authors:  Neerupma Silswal; Chad D Touchberry; Dorothy R Daniel; Darla L McCarthy; Shiqin Zhang; Jon Andresen; Jason R Stubbs; Michael J Wacker
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-07-22       Impact factor: 4.310

View more
  19 in total

Review 1.  Crosstalk between fibroblast growth factor 23, iron, erythropoietin, and inflammation in kidney disease.

Authors:  Jodie L Babitt; Despina Sitara
Journal:  Curr Opin Nephrol Hypertens       Date:  2019-07       Impact factor: 2.894

Review 2.  Regulation of FGF23: Beyond Bone.

Authors:  Petra Simic; Jodie L Babitt
Journal:  Curr Osteoporos Rep       Date:  2021-11-10       Impact factor: 5.096

Review 3.  Fibroblast Growth Factor 23 and αKlotho in Acute Kidney Injury: Current Status in Diagnostic and Therapeutic Applications.

Authors:  Javier A Neyra; Ming Chang Hu; Orson W Moe
Journal:  Nephron       Date:  2020-08-25       Impact factor: 2.847

Review 4.  UAB-UCSD O'Brien Center for Acute Kidney Injury Research.

Authors:  Lisa M Curtis; James George; Volker Vallon; Stephen Barnes; Victor Darley-Usmar; Sucheta Vaingankar; Gary R Cutter; Orlando M Gutierrez; Michael Seifert; Joachim H Ix; Ravindra L Mehta; Paul W Sanders; Anupam Agarwal
Journal:  Am J Physiol Renal Physiol       Date:  2021-03-29

Review 5.  Serum fibroblast growth factor 23 for early detection of acute kidney injury in critical illness.

Authors:  Shu Sun; Zhijia Liu; Changqing Chen; Zhisong Wang; Hailong Jin; Xiaoyun Meng; Bing Dai; Liming Zhang; Chenchen Zhou; Cheng Xue; Xiang Li
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

Review 6.  Bone function, dysfunction and its role in diseases including critical illness.

Authors:  Nan Su; Jing Yang; Yangli Xie; Xiaolan Du; Hangang Chen; Hong Zhou; Lin Chen
Journal:  Int J Biol Sci       Date:  2019-01-29       Impact factor: 6.580

Review 7.  FGF/FGFR signaling in health and disease.

Authors:  Yangli Xie; Nan Su; Jing Yang; Qiaoyan Tan; Shuo Huang; Min Jin; Zhenhong Ni; Bin Zhang; Dali Zhang; Fengtao Luo; Hangang Chen; Xianding Sun; Jian Q Feng; Huabing Qi; Lin Chen
Journal:  Signal Transduct Target Ther       Date:  2020-09-02

Review 8.  Klotho in Clinical Nephrology: Diagnostic and Therapeutic Implications.

Authors:  Javier A Neyra; Ming Chang Hu; Orson W Moe
Journal:  Clin J Am Soc Nephrol       Date:  2020-07-22       Impact factor: 8.237

9.  Glycerol-3-phosphate is an FGF23 regulator derived from the injured kidney.

Authors:  Petra Simic; Wondong Kim; Wen Zhou; Kerry A Pierce; Wenhan Chang; David B Sykes; Najihah B Aziz; Sammy Elmariah; Debby Ngo; Paola Divieti Pajevic; Nicolas Govea; Bryan R Kestenbaum; Ian H de Boer; Zhiqiang Cheng; Marta Christov; Jerold Chun; David E Leaf; Sushrut S Waikar; Andrew M Tager; Robert E Gerszten; Ravi I Thadhani; Clary B Clish; Harald Jüppner; Marc N Wein; Eugene P Rhee
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 19.456

10.  Significance of serum FGF-23 for risk assessment of contrast-associated acute kidney injury and clinical outcomes in patients undergoing coronary angiography.

Authors:  Shao-Sung Huang; Po-Hsun Huang; Hsin-Bang Leu; Tao-Cheng Wu; Jaw-Wen Chen; Shing-Jong Lin
Journal:  PLoS One       Date:  2021-07-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.